Extract from Ginkgo biloba leaves, its method of preparation and pharmaceuticals containing the extract

Abstract: The invention relates to an improved extract from Ginkgo biloba leaves, a method of preparation of the same and pharmaceuticals containing the extract.

Description: The invention relates to an improved extract from Ginkgo biloba leaves, a method of preparation of the extract and the pharmaceuticals containing the extract. Extracts from the leaves of Ginkgo biloba have been used for a long time for the therapy of peripheral and cerebral arterial circulatory disturbances. Methods of preparation of Ginkgo biloba extracts with a greatly enriched content of flavone glycosides as the active components are known; see DE-B 17 67 098 and DE-B 21 17 429. These extracts are also referred to as Ginkgo biloba monoextracts. EP-A 0 324 197 describes a method of preparation of an extract from Ginkgo biloba leaves in which an aqueous solution of a lower alcohol or ketone, obtained after extraction of the leaves, is concentrated in the presence of kieselguhr. The resultant aqueous suspension is filtered through kieselguhr, the fitrate is extracted with butanone and the extract is freed from the solvent. EP-A 330 567 relates to a method of preparation of an extract from Ginkgo biloba leaves in which the crushed leaves are extracted with an aqueous ketone compound. This extract is concentrated until biflavones and hydrophobic compounds precipitate. After filtration the aqueous concentrate is rendered alkaline, whereby the proanthocyanidins precipitate. After separation of the precipitate and acidification of the filtrate, a liquid-liquid-extraction is carried out with a C₄₋₆-ketone compound in the presence of ammonium sulfate. The extract is obtained after stripping of the ketone compound. EP-A-0 086 315 describes a method for preparation of an extract from the green leaves of Ginkgo biloba comprising the following steps: Extraction of the crushed leaves with a hydrocarbon, Extraction of the preextracted leaves with an acetone-water-mixture, liquid-liquid extraction with a water-immiscible ketone after adding ammonium sulfate, adsorption of the compounds with tannic acid properties on polyvinyl pyrrolidone, neutralization of the resultant filtrate, concentration of the solution to dryness, dissolving the residue in 41.5 percent by volume ethanol, filtration and drying. DE-A 35 14 054 has disclosed that the ginkgolides, known components of the Ginkgo biloba leaves which are terpenoid substances with lactone structure (see K. Nakanishi, Pure and Applied Chemistry, Vol. 14 (1967), 89-113, and M. Maruyama et al., Tetrahedron Letters (1967), 299-302 and 303-319, and K. Okabe et al., J. Chem. Soc. (1967), 2201-2206), can be used to treat illnesses and similar conditions caused by PAF ("Platelet Activating Factor"). The use of bilobalide, a further substance contained in the Ginkgo biloba leaves, is known from DE-A 33 38 995 and the corresponding US-A 4 571 407 for the treatment of demyelinating neuropathies, encephalopathies and cerebral edemas. Bilobalide is a sesquiterpene lactone structurally related to ginkgolides (see K. Nakanishi et al., R. T. Major et al., and K. Weinges et al., J. Am. Chem. Soc., Vol. 93 (1971), 3544-3546). Besides the compounds mentioned above, Ginkgo biloba leaves also contain so-called ginkgolic acids (anacardic acids). These compounds are 6-alkylsalicylic acids with n-C₁₃ - to n-C₁₉-alkyl groups with 0 to 3 double bonds; see J. L. Gellermann et al., Phytochemistry, Vol. 15 (1976), 1959-1961 and Analytic. Chem., Vol. 40 (1968), 739-743. "Ginkgol", a phenol substituted with the corresponding alkyl group, can be obtained either biogenetically by decarboxylation of the ginkgolic acids or during the technical processing of the Ginkgo biloba leaves; see Kawamura, Japan, J. Chem., Vol. 3 (1928), 91-93. The ginkgolic acids and ginkgols in Ginkgo biloba are accompanied by corresponding derivatives with a further phenolic hydroxyl group in 4-position, the 6-alkylresorcylic acids or 5-alkylresorcins; see J. Gellermann et al., Phytochemistry, Vol. 15 (1976), 1959-1961. These resorcin derivatives are responsible for the toxic effects and especially for the strong allergies and contact dermatitis caused by toxicodendron plants; see G. A. Hill et al., J. Am. Chem. Soc., Vol. 56 (1934), 2736-2738. Cases of strong allergic reactions after contact with Ginkgo fruits are known; see W.F. Sowers et al., Arch. Dermatol., Vol. 91 (1965), 452-456, and T. Nakamura, Contact Dermatitis, Vol. 12 (1985), 281-282. Serious mucosal disturbances after eating Ginkgo fruits have been described; see L. E. Becker and G. B. Skipworth, J. Am. Med. Assoc., Vol. 231 (1975), 1162-1163. Allergic skin reactions also occur occasionally on collecting or handling Ginkgo leaves. The significance of allergies caused by alkylphenol compounds from anacardiaceae and ginkgoaceae is evident from the development of substances and methods of desensitisation described in patent literature (see US-A 4 428 965) against the allergies caused by alkylphenol compounds. Commercial extracts from Ginkgo biloba leaves contain between 50 and 10,000 ppm ginkgolic acids. The extracts from Ginkgo biloba leaves prepared by the known methods in DE-B 17 67 098 and DE-B 21 17 429 are substantially free of alkylphenol compounds because the lipophilic components of the extract are removed by a liquid-liquid-extraction of the aqueous acetone extract with a substantially water-immiscible lipophilic solvent, e.g. with a chlorinated aliphatic lower hydrocarbon such as carbon tetrachloride. However, in this step, the therapeutically valuable ginkgolides and the bilobalide are also considerably reduced so that their content in the final product in Example 1 of DE-B 21 17 429 is a maximum of 0.5% in the case of ginkgolides A, B, C and J in total and approximately 0.3% in the case of bilobalide. The quantity of flavone glycosides, however, is greatly increased during this step, namely from 3 to 4% in the crude extract to approximately 24% in the final product. The object of the present invention therefore is to provide an extract from Ginkgo biloba leaves which is substantially free of alkylphenol compounds, has a high content of flavone glycosides and which contains substantially all of the ginkgolides and bilobalide present in the leaves used. A further object of the invention is to provide a method of preparation of the extract from Ginkgo biloba leaves which is substantially free of alkylphenol compounds and which has a high content of flavone glycosides, ginkgolides and bilobalide. The method of the present invention should, in contrast to the known methods in DE-B 17 67 098 and DE-B 21 17 429, succeed in removing the alkylphenol compounds without the use of chlorinated aliphatic hydrocarbons. The use of chlorinated hydrocarbons in technical processes is very problematic because of the occupational medical risks, the potential danger of these compounds to the environment and the possibility of undesirable residues in pharmaceuticals. Finally, it is the object of the invention to provide pharmaceuticals which contain this Ginkgo biloba extract with a high content of flavone glycosides, ginkgolides and bilobalide and where there is substantially no danger of allergic reactions, precisely because of the removal of the alkylphenol compounds. The invention therefore relates to an extract from Ginkgo biloba leaves which is substantially free of alkylphenol compounds, which has a high flavone glycoside content and which contains most of the ginkgolides and the bilobalide originally present in the leaves. The extract of the present invention contains 20 to 30 weight percent, in particular 22 to 26 weight percent, flavone glycosides, 2.5 to 4.5 weight percent of ginkgolides A, B, C and J (in total), 2.0 to 4.0 weight percent bilobalide, less than 10 ppm, in particular less than 1 ppm, alkylphenol compounds and less than 10 weight percent proanthocyanidins. In addition, the invention relates to a method of preparation of this Ginkgo biloba extract from Ginkgo biloba leaves which comprises the steps described in Claims 3 - 5. In contrast to the method of separating the lipophilic components described in DE-B 17 67 098, the aqueous alcohol or aqueous acetone crude extract is not directly subjected to liquid-liquid-extraction with a chlorinated aliphatic hydrocarbon, but rather most of the lipophilic components, which precipitate on distillation of the organic solvent components and dilution with water to a maximum content of 10 weight percent, preferably 5 weight percent, are separated by filtration. The alkylphenol compounds, the chlorophyll, the fatty acid derivatives and the biflavones precipitate due to their lower solubility in water and can be separated by filtration. Under these conditions, the desired components of the Ginkgo biloba extract remain dissolved. The alkylphenol compounds are reduced further to a content of less than 10 ppm in a subsequent degreasing step. The extract obtained by extraction of the aqueous solution with methylethylketone/acetone, according to Example 5 in DE-B 17 67 098, is freed from the solvent by distillation. The residue is dissolved in 20 to 60 percent of aqueous ethanol until it has a solids content of 5 to 20%, preferably approximately 10%, and to this solution is added an aqueous solution of a lead salt, as in Example 1 and 2 in DE-B 21 17 429. After separation of the lead precipitates, the aqueous ethanol solutions obtained can be subjected either directly or after dilution with water to a ethanol content of preferably 30%, to a multistage liquid-liquid-extraction with an aliphatic or cycloaliphatic hydrocarbon (boiling point of 60 to 100°C). The filtrate obtained after treatment with polyamide according to Example 3 (DE-B 21 17 429) can likewise be used either directly or after adjusting the ethanol content to approx. 30%. In pharmacological experimental models, the extract prepared according to the present invention has radical scavenging properties and properties which stimulate the circulation of blood, prevent ischemic disorders and inhibit platelet aggregations. In addition, the invention relates to pharmaceuticals which according to Claim 6 are characterized by a content of Ginkgo biloba extract. The Ginkgo biloba extract of the invention can be processed in the usual way for the preparation of pharmaceuticals e.g. to solutions, coated tablets, tablets or injection preparations. The pharmaceuticals in the invention are used for the treatment of peripheral and cerebral arterial circulatory disturbances. The examples illustrate the invention. Parts and percentage data refer to weight unless otherwise stated. Example 1 100 kg of dry Ginkgo biloba leaves are crushed in a mill to a particle size of less than 4 mm. After adding 750 kg of 60 weight percent aqueous acetone the mixture is stirred intensively for 30 minutes at a temperature of 57 to 59°C. The solid residue is separated by filtration or centrifugation and subjected to a second extraction under the same conditions. The extracts from the first and second extraction steps are combined. The ginkgolic acid content (based on the dry extract) equals approximately 13,000 ppm. The extract is concentrated under reduced pressure to a solids content of 30 to 40% and a maximum of approximately 5 weight percent acetone. By adding water, the concentrate is diluted to double volume and, while being stirred, left to cool to approximately 12°C. A precipitate forms which contains most of the ginkgolic acids, that is, the alkylphenol compounds, present in the leaves. After one hour at this temperature, the resultant precipitate is separated by centrifugation and discarded. The ginkgolic acid content in the resultant aqueous supernatant (based on the dry extract) equals approximately 320 ppm. 30 parts of ammonium sulfate are added to 100 parts of the aqueous solution. The mixture is stirred. After the ammonium sulfate has dissolved, a liquid-liquid-extraction is carried out twice with a mixture of methylethylketone and acetone in a ratio of 6 : 4 to 1 : 1, whereby the organic solvent added is the equivalent of half the volume of the aqueous solution and, after intensive stirring and pumping, the organic upper phase formed on completion of the mixing process is removed. The methylethylketone acetone solution is then concentrated under reduced pressure to a solids content of 50 to 70%. This concentrate is diluted with water and 95 weight percent ethanol so that a solution with 10 weight percent dry extract in 50 weight percent aqueous ethanol is obtained. While stirring intensively, an aqueous solution of lead hydroxide acetate is added in small quantities to this solution until there is a change in colour from brown to umber (brown with a green cast). The lead-tannin precipitate which forms is separated by centrifugation. The supernatant from the lead-tannin precipitation is subjected to a liquid-liquid-extraction with n-hexane in order to further remove the alkylphenol compounds. In this step, the alcohol-aqueous filtrate is stirred at least three times at room temperature, each time with 1/3 of its volume of n-hexane. The aqueous-alcohol extract solution is then concentrated under reduced pressure to an ethanol content of less than approximately 5%. 20 parts of ammonium sulfate are dissolved in 100 parts of this solution and then a liquid-liquid-extraction is carried out with a mixture of methylethylketone and ethanol in a volumetric ratio of 6 : 4, whereby extraction with the organic solvent mixture is carried out twice, each time with the equivalent of half the volume of the aqueous solution. The organic phase is separated and stirred with 20% of its weight of ammonium sulfate. A possible phase of water and the undissolved ammonium sulfate are removed. The clear extract solution is concentrated to a solids content of 50 to 70 weight percent. This concentrate is dried under reduced pressure at a maximum product temperature of 60 to 80°C to a dry extract with a water content of less than 5%. From 100 kg of Ginkgo leaves, 2.5 kg of Ginkgo biloba extract with a content of approximately 24 weight percent flavone glycosides, approximately 3.6 weight percent ginkgolides, approximately 2.9 weight percent bilobalide, approximately 6.5 weight percent proanthocyanidins and less than 1 ppm alkylphenol compounds are obtained. Example 2 Solution for oral administration: 100 ml solution contains: Example 3 Coated tablets: 1 tablet contains:

Claims: Claims for the following Contracting States : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE Extract from the leaves of Ginkgo biloba, containing 20 to 30 weight percent flavon glycosides, 2.5 to 4.5 weight percent of ginkgolides A, B, C an J (in total), 2.0 to 4.0 weight percent bilobalide, less than 10 ppm alhylphenol compounds and less than 10 weight percent proanthocyanidins. Extract according to Claim 1, containing 22 to 26 weight percent flavone glycosides, 2.5 to 4.5 weight percent of ginkgolides A, B, C and J (in total), 2.0 to 4.0 weight percent bilobalide, less than 1 ppm alkylphenol compounds and less than 10 weight percent proanthocyanidins. Method of preparation of an extract from Ginkgo biloba leaves according to claim 1 or 2; characterized in that (a) the fresh or dried green leaves of Ginkgo biloba are extracted at a temperature of approximately 40 to 100°C with aqueous acetone, an aqueous alkanol of 1 to 3 C-atoms or anhydrous methanol, (b) most of the organic solvent is separated from the extract to a maximum content of 10 weight percent, whereby water can be added in the last steps of distillation, (c) the remaining concentrated aqueous solution is diluted with water to a solids content of 5 to 25 weight percent left to cool, while being stirred, to a temperature below 25°C left to stand until a precipitate forms and the resultant precipitate, consisting of the lipophilic components which do not dissolve well in water, is removed, (d) ammonium sulfate is added to the remaining aqueous solution and the solution formed is extracted with methylethylketone or a mixture of methylethylketone and acetone, (e) the extract obtained is concentrated to a solids content of 50 to 70% and the concentrate obtained is diluted with water and ethanol so that a solution is obtained which contains 50 weight percent of water and 50 weight percent of ethanol with a solids content of 10 weight percent, (f) an aqueous solution of a lead salt is added to the thus obtained solution until a change in colour from brown to umber takes place, and the precipitate formed is removed, or a polyamid is used instead of a lead salt, (g) the remaining aqueous-alcohol solution is extracted with an aliphatic or cycloaliphatic solvent with a boiling point of 60 to 100°C in order to further remove the alkylphenol compounds, (h) the remaining aqueous-alcohol solution is concentrated under reduced pressure to a maximum ethanol content of approximately 5% and ammonium sulfate is added up to a content of 20 weight percent, (i) the solution obtained is extracted with a mixture of methylethylketone and ethanol in a ratio of 8 : 2 to 5 : 5, preferably 6 : 4, (k) the resultant organic phase is concentrated to a solids content of 50 to 70 weight percent, (l) the resultant concentrate is dried under reduced pressure at a maximum temperature of 60 to 80°C to a dry extract with a water content of less than 5%. Method according to claim 3, characterized in that in step b) the organic solvent is separated to a maximum content of 5 weight percent, in step c) the aqueous solution is diluted with water to a solids content of 15 to 20 weight percent and is cooled to a temperature of approximately 10 to 12°C, in step d) ammonium sulfate is added to the solution to give a content of 30 weight percent and the solution formed is extracted with the solvent in a ratio of 9:1 to 4:6, preferably 6:4, and in step f) lead acetate, lead hydroxide acetate or lead nitrate or an aqueous suspension of lead hydroxide is used. Method according to Claim 4, characterized in that polyamide-6, polyamide-6,6 or cross-linked polyvinyl pyrrolidone (polyvidon) is used in step (f) instead of a lead salt. Pharmaceutical composition, characterized by a content of Ginkgo biloba extract according to Claim 1 or 2 or obtainable according to any of Claims 3 to 5. Claims for the following Contracting States: ES, GR Extract from the leaves of Ginkgo biloba, containing 20 to 30 weight percent flavone glycosides, 2.5 to 4.5 weight percent of ginkgolides A, B, C and J (in total), 2.0 to 4.0 weight percent bilobalide, less than 10 ppm alkylphenol compounds and less than 10 weight percent proanthocyanidins. Extract according to Claim 1, contianing 22 to 26 weight percent flavone glycosides, 2.5 to 4.5 weight percent of ginkgolides A, B, C and J (in total), 2.0 to 4.0 weight percent bilobalide, less than 1 ppm alkylphenol compounds and less than 10 weight percent proanthocyanidins. Method of preparation of an extract from Ginkgo biloba leaves according to claim 1 or 2; characterized in that (a) the fresh or dried green leaves of Ginkgo biloba are extracted at a temperature of approximately 40 to 100°C with aqueous acetone, an aqueous alkanol of 1 to 3 C-atoms or anhydrous methanol, (b) most of the organic solvent is separated from the extract to a maximum content of 10 weight percent, whereby water can be added in the last steps of distillation, (c) the remaining concentrated aqueous solution is diluted with water to a solids content of 5 to 25 weight percent left to cool, while being stirred, to a temperature below 25°C left to stand until a precipitate forms and the resultant precipitate, consisting of the lipophilic components which do not dissolve well in water, is removed, (d) ammonium sulfate is added to the remaining aqueous solution and the solution formed is extracted with methylethylketone or a mixture of methylethylketone and acetone, (e) the extract obtained is concentrated to a solids content of 50 to 70% and the concentrate obtained is diluted with water and ethanol so that a solution is obtained which contains 50 weight percent of water and 50 weight percent of ethanol with a solids content of 10 weight percent, (f) an aqueous solution of a lead salt is added to the thus obtained solution until a change in colour from brown to umber takes place, and the precipitate formed is removed, or a polyamid is used instead of a lead salt, (g) the remaining aqueous-alcohol solution is extracted with an aliphatic or cycloaliphatic solvent with a boiling point of 60 to 100°C in order to further remove the alkylphenol compounds, (h) the remaining aqueous-alcohol solution is concentrated under reduced pressure to a maximum ethanol content of approximately 5% and ammonium sulfate is added up to a content of 20 weight percent, (i) the solution obtained is extracted with a mixture of methylethylketone and ethanol in a ratio of 8 : 2 to 5 : 5, preferably 6 : 4, (k) the resultant organic phase is concentrated to a solids content of 50 to 70 weight percent, (l) the resultant concentrate is dried under reduced pressure at a maximum temperature of 60 to 80°C to a dry extract with a water content of less than 5%. Method according to claim 3, characterized in that in step b) the organic solvent is separated to a maximum content of 5 weight percent, in step c) the aqueous solution is diluted with water to a solids content of 15 to 20 weight percent and is cooled to a temperature of approximately 10 to 12°C, in step d) ammonium sulfate is added to the solution to give a content of 30 weight percent and the solution formed is extracted with the solvent in a ratio of 9:1 to 4:6, preferably 6:4, and in step f) lead acetate, lead hydroxide acetate or lead nitrate or an aqueous suspension of lead hydroxide is used. Method according to Claim 4, characterized in that polyamide-6, polyamide-6,6 or cross-linked polyvinyl pyrrolidone (polyvidon) is used in step (f) instead of a lead salt. Pharmaceutical composition, characterized by content of Ginkgo biloba extract according to Claim 1 or 2 or obtainable according to any of Claims 3 to 5. A method for preparing a pharmaceutical composition comprising combining the Ginkgo Biloba extract according to claim 1 or 2 or obtainable according to any of claims 3 to 5 with a Pharmaceutically acceptable carier.

Inventors: SCHWABE KLAUS-PETER DR, SCHWABE, KLAUS-PETER, DR.
Applicants: SCHWABE WILLMAR GMBH & CO, DR. WILLMAR SCHWABE GMBH & CO.
Application year: 1990
Main classification: A61K35
IPC codes: A61P9, A61K36